NCT06863311View on ClinicalTrials.gov

Trial of XL092 in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Advanced Renal Cell CarcinomaMetastatic Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
Interventions
DRUG

XL092

100 mg orally

DRUG

Nivolumab

480 mg intravenously.

Trial Locations (1)

10032

RECRUITING

Columbia University Irving Medical Center, New York

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

collaborator

Columbia University

OTHER

lead

Karie Runcie

OTHER